All In Biotech

Drug Trial Radar · NCT01828099

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

376

Actual

Start

Jul 9, 2013

Primary completion

Jun 24, 2016

Study completion Jan 7, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV, non-squamous non-small cell lung cancer (NSCLC) harboring a confirmed anaplastic lymphoma kinase (ALK) rearrangement, using the Ventana immunohistochemistry (IHC) test.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • CeritinibDrug

    Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule.

  • PemetrexedDrug

    Pemetrexed was administered at a dose of 500 mg/m\^2 as an intravenous (iv) infusion on Day 1 of each 21-day cycle

  • CisplatinDrug

    Cisplatin was administered by iv infusion at a dose of 75 mg/m\^2 every 21 days for up to 4 cycles.

  • CarboplatinDrug

    Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC)Time frame: From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months

Locations

167 sites in 29 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    La Rioja, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Auckland, Australia

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia

  • Novartis Investigative Site

    Heidelberg, Victoria, Australia

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil

  • Novartis Investigative Site

    Rio de Janiero, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Natal, Rio Grande do Norte, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Itajaí, Santa Catarina, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São José do Rio Preto, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Chongqing, China

  • Novartis Investigative Site

    Chongqing, China

  • Novartis Investigative Site

    Guang Dong Province, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Changchun, Jilin, China

  • Novartis Investigative Site

    Changchun, Jilin, China

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, China

  • Novartis Investigative Site

    Xi’an, Shanxi, China

  • Novartis Investigative Site

    Chengdu, Sichuan, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Montería, Colombia

  • Novartis Investigative Site

    Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site

    Herlev, Denmark

  • Novartis Investigative Site

    Odense C, Denmark

  • Novartis Investigative Site

    Caen, France

  • Novartis Investigative Site

    Grenoble, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Paris, France

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.